Management of Hypomethylating Agent (HMA) Failure in Myelodysplastic Syndromes (MDS)
 | Management of Hypomethylating Agent (HMA) Failure in Myelodysplastic Syndromes (MDS) CME, CPE Jamile M. Shammo, MD, FASCP, FACP | |
| Release Date: May 07, 2021 Expiration Date: May 07, 2022 | ||
Join Dr. Jamile Shammo as she explores challenges and advances in the management of hypomethylating agent (HMA) failure in myelodysplastic syndromes (MDS). Topics will include potential mechanisms of resistance, distinguishing between HMA failure and HMA-related cytopenia, current standard care following HMA failure, and notable clinical trials for treatment of MDS patients with HMA failure. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol-Myers Squibb and Taiho Oncology, Inc. | ||
| Begin, Earn CreditView Only, No Credit | ||